Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a research report issued on Wednesday. They presently have a $109.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 170.00% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Tuesday, July 26th. Mizuho reaffirmed a “buy” rating and set a $64.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 20th. Brean Capital cut shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 1st. Cowen and Company reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Tuesday. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $81.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, August 3rd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $74.00.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 40.37 on Wednesday. The company’s 50 day moving average is $41.65 and its 200-day moving average is $45.42. Pacira Pharmaceuticals has a 12 month low of $31.08 and a 12 month high of $80.25. The firm’s market cap is $1.50 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/wedbush-reaffirms-outperform-rating-for-pacira-pharmaceuticals-inc-pcrx-2.html

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to the consensus estimate of $67.80 million. Pacira Pharmaceuticals had a negative net margin of 4.21% and a positive return on equity of 0.02%. The firm’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.20 earnings per share. Equities research analysts predict that Pacira Pharmaceuticals will post $0.42 EPS for the current year.

In other Pacira Pharmaceuticals news, President James S. Scibetta sold 25,000 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $45.21, for a total transaction of $1,130,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David M. Stack sold 15,000 shares of the business’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $45.32, for a total value of $679,800.00. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of PCRX. BlackRock Institutional Trust Company N.A. increased its position in shares of Pacira Pharmaceuticals by 0.7% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 908,647 shares of the company’s stock valued at $48,140,000 after buying an additional 5,903 shares during the last quarter. Daruma Capital Management LLC increased its position in shares of Pacira Pharmaceuticals by 1.6% in the first quarter. Daruma Capital Management LLC now owns 963,184 shares of the company’s stock valued at $51,029,000 after buying an additional 14,901 shares during the last quarter. State Street Corp increased its position in shares of Pacira Pharmaceuticals by 4.4% in the first quarter. State Street Corp now owns 1,109,611 shares of the company’s stock valued at $58,792,000 after buying an additional 47,096 shares during the last quarter. BlackRock Group LTD increased its position in shares of Pacira Pharmaceuticals by 17.7% in the first quarter. BlackRock Group LTD now owns 23,054 shares of the company’s stock valued at $1,221,000 after buying an additional 3,472 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Pacira Pharmaceuticals by 122.7% in the first quarter. BlackRock Inc. now owns 2,497 shares of the company’s stock valued at $133,000 after buying an additional 1,376 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

5 Day Chart for NASDAQ:PCRX

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.